Exhibit 99.1

Amended Loan Schedule to Secured Promissory Note dated November 10, 2022
between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC
	Date	Principal	Aggregated Principal
Original Secured Promissory Note	11/10/2022	$2,319,279	$2,319,279
Additional loans to be included:
Loan #1	12/22/2022	$250,000	$2,569,279
Loan #2	1/19/2023	$250,000	$2,819,279
Loan #3	2/22/2023	$250,000	$3,069,279
Loan #4	3/20/2023	$250,000	$3,319,279
Loan #5	5/19/2023	$150,000	$3,469,279
Loan #6	7/10/2023	$200,000	$3,669,279
Loan #7	7/28/2023	$250,000	$3,919,279
Loan #8	8/30/2023	$250,000	$4,169,279
Loan #9	10/11/2023	$250,000	$4,419,279
Loan #10	12/04/2023	$250,000	$4,669,279
Loan #11	1/08/2024	$250,000	$4,919,279
Loan #12	2/14/2024	$250,000	$5,169,279
Loan #13	3/14/2024	$250,000	$5,419,279
Loan #14	5/10/2024	$200,000	$5,619,279
Loan #15	6/03/2024	$75,000	$5,694,279
Loan #16	6/14/2024	$200,000	$5,894,279
Loan #17	7/03/2024	$150,000	$6,044,279
Loan #18	7/22/2024	$100,000	$6,144,279
Loan #19	8/19/2024	$125,000	$6,269,279
Loan #20	9/20/2024	$100,000	$6,369,279
Loan #21	9/30/2024	$150,000	$6,519,279
Loan #22	10/11/2024	$100,000	$6,619,279
Loan #23	10/28/2024	$100,000	$6,719,279

ACURA PHARMACEUTICALS, INC.

By: /s/ Robert A. Seiser

Robert A. Seiser

Senior Vice President & Chief Financial Officer

Date: November 2, 2024